Search Results - "CURT, G. A"

Refine Results
  1. 1

    Fatigue in cancer by Curt, Gregory A

    Published in BMJ (30-06-2001)
    “…Regular bed and waking times should be established, and the patient should perform restful activities before going to bed. 4 Although rest is commonly advised…”
    Get full text
    Journal Article
  2. 2

    Impact of Cancer‐Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition by Curt, Gregory A., Breitbart, William, Cella, David, Groopman, Jerome E., Horning, Sandra J., Itri, Loretta M., Johnson, David H., Miaskowski, Christine, Scherr, Susan L., Portenoy, Russell K., Vogelzang, Nicholas J.

    Published in The oncologist (Dayton, Ohio) (01-10-2000)
    “…Purpose. This survey was designed to confirm the prevalence and duration of fatigue in the cancer population and to assess its physical, mental, social, and…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow by KOIZUMI, S, CURT, G. A, FINE, R. L, GRIFFIN, J. D, CHABNER, B. A

    Published in The Journal of clinical investigation (01-03-1985)
    “…Immature myeloid precursor cells were preferentially selected from normal human bone marrow by using immune rosette techniques that employed monoclonal…”
    Get full text
    Journal Article
  10. 10

    Effect of calcium channel blockers on human CFU-GM with cytotoxic drugs by Fine, R L, Koizumi, S, Curt, G A, Chabner, B A

    Published in Journal of clinical oncology (01-03-1987)
    “…Calcium channel blockers (CCBs) such as verapamil and nitrendipine are capable of increasing drug sensitivity in resistant murine and human tumor cells. This…”
    Get more information
    Journal Article
  11. 11

    Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate by CURT, G. A, JOLIVET, J, CARNEY, D. N, BAILEY, B. D, DRAKE, J. C, CLENDENINN, N. J, CHABNER, B. A

    Published in The Journal of clinical investigation (01-10-1985)
    “…We have characterized the determinants of methotrexate (MTX) responsiveness in eight patient-derived cell lines of small-cell lung cancer (SCLC). Clonogenic…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512) by WEISS, R. B, GREENE, R. F, KNIGHT, R. D, COLLINS, J. M, PELOSI, J. J, SULKES, A, CURT, G. A

    Published in Cancer research (Chicago, Ill.) (15-10-1988)
    “…We have conducted a Phase I and pharmacological study of flavone acetic acid, one of a series of novel flavonoids. The drug was administered i.v. weekly for 4…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16

    Reversible acute pulmonary edema due to uncontrolled hyperglycemia in diabetic individuals with renal failure by Kaldany, A, Curt, G A, Estes, N M, Weinrauch, L A, Christlieb, A R, D'Elia, J A

    Published in Diabetes care (01-09-1982)
    “…Reversible acute pulmonary edema due to uncontrolled hyperglycemia in diabetic individuals with renal failure. A Kaldany , G A Curt , N M Estes , L A Weinrauch…”
    Get full text
    Journal Article
  17. 17

    The use of animal models in cancer drug discovery and development by Curt, G A

    Published in Stem cells (Dayton, Ohio) (01-01-1994)
    “…The process of searching for new cancer drugs has evolved from rational empiricism using high volume murine screens towards more targeted systems designed to…”
    Get more information
    Journal Article
  18. 18

    Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas by CURT, G. A, KELLEY, J. A, KUFTA, C. V, SMITH, B. H, KORNBLITH, P. L, YOUNG, R. C, COLLINS, J. M

    Published in Cancer research (Chicago, Ill.) (01-12-1983)
    “…2,5-Diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone (AZQ; Diaziquone, NSC 182986) is a rationally designed antitumor drug possessing sufficient lipid…”
    Get full text
    Journal Article
  19. 19
  20. 20

    A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880) by CURT, G. A, KELLEY, J. A, FINE, R. L, HUGUENIN, P. N, ROTH, J. S, BATIST, G, JENKINS, J, COLLINS, J. M

    Published in Cancer research (Chicago, Ill.) (01-07-1985)
    “…5,6-Dihydro-5-azacytidine (DHAC; NSC 264880) is an analogue of 5-azacytidine that does not possess the hydrolytically unstable 5,6-imino bond of the parent…”
    Get full text
    Journal Article